Mycobacterium indicus pranii therapy induces tumor regression in MyD88- and TLR2-dependent manner

Pawan Kumar1,2, Gobardhan Das3 and Sangeeta Bhaskar1*

Abstract

Objectives: Mycobacterium indicus pranii (MIP) is an atypical mycobacterium species with potent antitumor efficacy. Macrophages and dendritic cells (DCs) are antigen-presenting cells, playing key roles in the activation of antitumor immunity. We have previously shown the potent activation of macrophages and DCs by MIP, which is mediated by MyD88–TLR2 signaling axis. In the present study, we further examined the role of MyD88 and TLR2 in MIP-mediated tumor regression.

Results: Wild-type and MyD88−/− mice were implanted with B16F10 tumor cells, treated with MIP or phosphate-buffered saline (PBS) and monitored for tumor growth. As expected, MIP therapy led to significant tumor regression in wild-type mice. However, antitumor efficacy of MIP was lost in MyD88−/− animals. Both PBS-treated (control) and MIP-treated MyD88−/− mice developed tumors with comparable volume. Since MyD88 relays TLR engagement signals, we analyzed the antitumor efficacy of MIP in TLR2−/− and TLR4−/− mice. It was observed that MIP therapy reduced tumor burden in wild-type and TLR4−/− mice but not in TLR2−/− mice. Tumor volume in MIP-treated TLR2−/− mice were comparable with those in PBS-treated wild-type animals. These results implicated the MyD88–TLR2 signaling axis in the antitumor efficacy of MIP.

Keywords: Mycobacterium indicus pranii, Tumor regression, TLR, MyD88, Mouse tumor model

Introduction

Mycobacterium indicus pranii (MIP) is an atypical mycobacterium possessing strong immunomodulatory properties [1]. It was selected from a panel of mycobacteria for evoking cell-mediated immunity against M. leprae and was approved for the treatment of leprosy in 1998. Small clinical studies, wherein MIP was evaluated against head and neck cancer, bladder cancer, and lung cancer, also suggested the potent antitumor efficacy of MIP [2, 3]. Mycobacterium species vary widely in their antigenicity and biochemical properties. Recent studies have uniquely placed MIP between slow- and fast-growing mycobacteria [4]. Whole-genome sequencing has revealed the higher levels of putative antigenic molecules in MIP, compared with BCG [1].

We have shown previously that MIP therapy results in significant tumor regression and prolongs the survival of tumor-bearing mice [5]. Immunological studies in these animals revealed that MIP therapy promotes tumor-specific T cell responses and NK cell cytotoxicity [5]. It has been shown that macrophages and dendritic cells (DCs) play key roles in the processing and presentation of tumor antigens and mounting of antitumor immunity. Consistently, MIP was found to activate macrophages and DCs and induce Th1 polarization potential in these cells [6, 7]. It was further observed that MIP led to macrophage and DC activation in MyD88- and TLR2-dependent manner [6, 7].

In this study, we explored the role of MyD88 and TLRs in MIP-induced tumor regression. Mice were implanted with B16F10 melanoma cells, treated with MIP and monitored for tumor growth. It was observed that MIP
therapy resulted in significant tumor regression in wild-type, but not in MyD88−/− mice. Experiments with TLR knockout mice demonstrated that MIP induced comparable tumor regression in wild-type and TLR4−/− mice. However, antitumor efficacy of MIP was significantly reduced in TLR2−/− mice. These findings shed light on the innate immune mechanisms involved in the antitumor efficacy of MIP.

Main text

Materials and methods
C57BL/6 and MyD88−/− mice (age 6–8 week) were obtained from the animal house facility of the National Institute of Immunology, New Delhi, India. TLR2−/− and TLR4−/− mice were a kind gift from Dr. Ruslan Medzhitov (Yale University School of Medicine, New Haven, CT). MIP was cultured in Middlebrook 7H9 broth (BD Difco) supplemented with 0.1% Glycerol, 0.05% Tween 80 and 10% albumin-dextrose-catalase enrichment (BD Difco) in a shaking incubator at 37 °C. For MIP therapy, bacilli were harvested, washed and suspended in PBS, and autoclaved for 15 min at 15 lb/in² pressure. Tumors were implanted by s.c. injecting 3.0 × 10⁴ B16F10 cells in the right flank of mice. For MIP therapy, mice were injected peritumorally with 5 × 10⁶ bacilli per 100 μl PBS using dose-schedule shown in Fig. 1a. Control animals were injected with 100 μl PBS using the same schedule. To monitor tumor growth, tumor dimensions were measured with the help of Bernier’s caliper. Tumor volume were calculated using the formula V = 0.5 × L × W × W, where V is tumor volume, L is longer dimension and W is the shorter dimension of tumor. Animals were euthanized after experiments were over by CO₂ asphyxiation method. Data were analyzed by one way ANOVA (with Tukey’s multiple comparison test applied post-analysis) using GraphPad Prism 5 software.

Results
Since macrophages and DCs play a key role in mounting of antitumor immunity and are activated by MIP in a MyD88-dependent manner, we asked whether MyD88 also plays a role in the antitumor efficacy of MIP. For this, wild-type and MyD88−/− mice were implanted with B16F10 melanoma cells, treated with MIP and monitored for tumor growth. It was observed that MIP treatment resulted in significant tumor regression in wild-type mice, compared with PBS-treated control animals (Fig. 1b). However, the antitumor efficacy of MIP was drastically reduced in MyD88−/− mice. MIP-treated MyD88−/− mice and control animals developed tumors with comparable volume (Fig. 1b). These results showed the key role of MyD88-dependent signaling in MIP-induced tumor regression.

Discussion
The antitumor efficacy of MIP has been demonstrated by both human and animal studies. However, the underlying immune mechanism of MIP-mediated tumor regression remains poorly understood. Here, we explored the roles of...
MyD88 and TLRs in the antitumor efficacy of MIP for the first time. MyD88 is an adapter protein involved in relaying TLR engagement signals across the plasma membrane [8]. We observed that tumor regression efficacy of MIP was drastically reduced in MyD88\(^{-/-}\) mice. Tumors in MIP-treated MyD88\(^{-/-}\) mice were larger in size, compared

![Figure 2](image)

**Fig. 2** TLR2 plays a key role in the antitumor efficacy of MIP. Wild-type and TLR knockout mice were implanted with B16F10 tumor cells in their right flank, treated with MIP and monitored for tumor growth. Lower tumor volume were observed in MIP-treated wild-type mice, compared with PBS-treated control animals (a, b). MIP-treated TLR2\(^{-/-}\) mice developed large size tumors, as developed by PBS-treated wild-type animals (c). MIP-treated TLR4\(^{-/-}\) mice developed tumors comparable with those in MIP-treated wild-type animals (d). Each curve represents tumor volume in an individual animal. Mean ± SEM of tumor volume in different animal groups on day 21 are shown in the form of bar graph (e). Representative data of the one of two independent experiments are shown.
with other groups. Macrophages and DCs are instrumental in mounting of antitumor immunity. Consistent with the above findings, MIP has been shown to activate these cells in a MyD88-dependent manner [6, 7]. *Mycobacterium bovis* BCG is also a potent inducer of antitumor immunity and is used for the treatment of superficial bladder cancer [9]. Similar to our results, Akazawa et al. have shown that the antitumor efficacy of BCG cell-wall skeleton vanishes in MyD88−/− animals [10]. Interestingly, we observed moderately increased tumor volume in MIP-treated MyD88−/− mice, compared with untreated mice. A plausible explanation for this could be drawn from our previous study, wherein we have shown that BCG-stimulated MyD88-deficient DCs secrete substantial amount of inflammatory cytokines but are inefficient in IL-10 secretion [11]. A similar overinflammatory environment in MIP-treated MyD88−/− mice could lead to increased tumor cell growth, resulting in larger tumor volume.

Next, we examined the involvement of TLRs in MIP-mediated tumor regression. Mycobacteria are known to engage TLR2, TLR4 and TLR9 [12]. We observed that MIP induced significant tumor regression in TLR4−/− mice, but its antitumor efficacy was substantially reduced in TLR2−/− mice. These findings demonstrated that TLR2, but not TLR4 plays a key role in MIP-induced tumor regression. In keeping with these findings, immunostimulatory properties of MIP have been shown to be lost in TLR2-deficient macrophages and DCs [6, 7]. Characterization of TLR2 signaling by heat-killed MIP has shown that TLR2/TLR1 heterodimers play a predominant role in the recognition of the bacilli [7]. Similar to MIP, a synthetic lipoprotein with TLR2/TLR1 engaging property has also been shown to induce tumor regression in the mouse model [13]. Lipoprotein treatment was found to enhance cytotoxic T cell responses and reduce immunosuppressive functions of FoxP3+ regulatory T cells [13]. Interestingly, we had also observed higher CTL and NK cell cytotoxicity and reduction of FoxP3+ regulatory T cell levels in tumor mass and draining lymph nodes of MIP-treated animals [5].

This study builds upon our previous observations and demonstrates the importance of TLR2 and MyD88 in MIP-mediated tumor regression. Since TLR–MyD88 signaling axis is a key component of innate immunity, these findings implicate the innate immune system in the antitumor efficacy of MIP.

**Limitation**

In the present manuscript, we have explored the role of MyD88–TLR signaling axis in the antitumor efficacy of MIP using mouse tumor model. Therefore, these results are specifically valid for the mouse model only.

**Abbreviations**

MIP: *Mycobacterium indicus pranii*; BCG: *Bacillus Calmette–Guerin*; TLR: toll-like receptor; PBS: phosphate-buffered saline; DC: dendritic cell; CTL: cytotoxic T lymphocyte.

**Acknowledgements**

The authors are thankful to Dr. P. Nagarajan, In-charge, Small Animal Facility, NII, New Delhi for his support during animal work.

**Authors’ contributions**

PK carried out experiments. PK, GD and SB planned the study and analyzed the data. PK, GD and SB prepared the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by the core research grant from the National Institute of Immunology, New Delhi. Funding body did not play any role in study design, data analysis and manuscript preparation.

**Availability of data and materials**

Data is available upon reasonable request.

**Ethics approval and consent to participate**

This work was approved by the Ethical Review Board of the National Institute of Immunology, New Delhi (IAEC Approval No. 205/08/13).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. PDC-I, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India.
2. Present Address: Dept. of Preventive Oncology, Dr. B. R. Ambedkar Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
3. Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi 110067, India.

**Received: 18 February 2019   Accepted: 28 September 2019**

**Published online:** 07 October 2019

**References**

1. Saini V, et al. Massive gene acquisitions in *Mycobacterium indicus pranii* provide a perspective on mycobacterial evolution. Nucleic Acids Res. 2012;40(21):10832–50.
2. Sur P, Dastidar A. Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer). J Indian Med Assoc. 2012;40(21):10832–50.
3. Kumar P, et al. Polyphasic taxonomic analysis establishes *Mycobacterium indicus pranii* as a distinct species. PLoS ONE. 2009;4(7):e6263.
4. Ahmad F, et al. Polyphasic taxonomic analysis establishes *Mycobacterium indicus pranii* as a distinct species. PLoS ONE. 2009;4(7):e6263.
5. Ahmad F, et al. Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. PLoS ONE. 2011;6(9):e25424.
6. Kumar P, et al. Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner. J Leukoc Biol. 2015;97(3):S11–20.
7. Kumar P, et al. Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner. Immunology. 2014;143(2):258–68.
8. Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep. 2014;6:9.
9. Kawai K, et al. Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22–7.

**Corresponding author**

Dr. Surjeet Singh

Department of Preventive Oncology

Dr. B. R. Ambedkar Cancer Hospital

All India Institute of Medical Sciences

Ansari Nagar

New Delhi 110029

India.

**Email:** surjeet.singh@aiims.ac.in
10. Akazawa T, et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Can Res. 2004;64(2):757–64.

11. Kumar P, Bhaskar S. Myeloid differentiation primary response protein 88 (MyD88)-deficient dendritic cells exhibit a skewed cytokine response to BCG. BMC Res Notes. 2019;12(1):52.

12. Basu J, Shin D-M, Jo E-K. Mycobacterial signalling through toll-like receptors. Front Cell Infect Microbiol. 2012;2:145.

13. Zhang Y, et al. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol. 2011;186:1963.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions